CAS |
1012054-59-9 |
Content |
Purity≥98% |
English Name |
CUDC-101 |
Synonym |
CUDC101 |
Unit |
Piece |
Purity |
≥98% |
Molecular Formula |
C24H26N4O4 |
Molecular Weight |
434.49 |
Appearance |
White to yellow solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO |
MDL |
MFCD15528940 |
InChIKey |
PLIVFNIUGLLCEK-UHFFFAOYSA-N |
InChI |
InChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27) |
PubChem CID |
24756910 |
SMILES |
C#CC1=CC=CC(NC2=NC=NC3=CC(OC)=C(C=C23)OCCCCCCC(NO)=O)=C1 |
Description |
CUDC-101 is a potent HDAC, EGFR and HER2 inhibitor. |
Target Point |
EGFR;HDAC;HER2 |
Passage |
Angiogenesis; Protein Tyrosine Kinase/RTK |
Data Literature Source |
[1]. Xiong Cai et al Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer J. Med. Chem., 2010, 53 (5), pp 2000–2009
[2]. Sun H, et al. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Horm Cancer. 2016 Jun;7(3):196-210.
[3]. Zhang L, et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget. 2015 Apr 20;6(11):9073-85.
[4]. Lai CJ, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.Cancer Res. 2010 May 1;70(9):3647-56. Epub 2010 Apr 13 |
Specification |
5mg 10mg |